Irini Chatziralli1, George Theodossiadis2,3, Efstratios Parikakis1, Ioannis Datseris4, Panagiotis Theodossiadis5. 1. 2nd Department of Ophthalmology, Ophthalmiatrion Athinon, Athens, Greece. 2. 2nd Department of Ophthalmology, Henry Dunant Hospital, Athens, Greece. theodossiadisg@ath.forthnet.gr. 3. , 13 Lykiou street, 10674, Athens, Greece. theodossiadisg@ath.forthnet.gr. 4. Ophthalmological Institute of Athens, Athens, Greece. 5. 2nd Department of Ophthalmology, University of Athens, Attikon Hospital, Athens, Greece.
Abstract
PURPOSE: To evaluate prospectively the anatomical and functional results after ocriplasmin injection in patients with vitreomacular traction (VMT), or macular hole (MH) combined with VMT, providing the real-life experience of three centers, using spectral domain-optical coherence tomography (SD-OCT). METHODS: Twenty-four patients with VMT (17 with VMT alone and 7 with an MH combined with VMT) were treated with a single ocriplasmin injection and followed-up prospectively at baseline, day 1, 7, 28 and the last examination of the follow-up for each patient (range: 30-127 days). Best-corrected visual acuity (BCVA) and SD-OCT were performed for patient assessment, while various adverse events were recorded and analysed. At baseline, univariate analysis was also performed to examine the potential predictive factors for VMT release. RESULTS: 66.7 % of patients presented VMT release at the end of the follow-up, while 28.6 % exhibited MH closure. Baseline positive predictive factors for VMT release were young age, being female, phakic lens status, increased vitreofoveal angle, V-shaped and loose vitreomacular adhesion, small adhesion area, thin vitreous strands at the adhesion site and absence of an epiretinal membrane. Four new cases of ellipsoid line changes and subretinal fluid development became evident at day 7 compared to baseline. Lamellar macular hole (LMH) in four cases was first noticed at day 28 post injection. Formation of cystoid macular edema (CME) was noticed in three new cases at day 28 compared to baseline. CONCLUSIONS: Our study demonstrated a VMT release rate of 66.7 %. Apart from the known baseline factors that influence VMT release after ocriplasmin injection, the size of the vitreofoveal angle, a V-shaped and loose vitreomacular adhesion, a small adhesion area, and thin vitreous strands at the adhesion site, could additionally affect the outcome of VMT release. In addition, we studied when VMT release and concomitant events occur and for how long the induced complications lasted.
PURPOSE: To evaluate prospectively the anatomical and functional results after ocriplasmin injection in patients with vitreomacular traction (VMT), or macular hole (MH) combined with VMT, providing the real-life experience of three centers, using spectral domain-optical coherence tomography (SD-OCT). METHODS: Twenty-four patients with VMT (17 with VMT alone and 7 with an MH combined with VMT) were treated with a single ocriplasmin injection and followed-up prospectively at baseline, day 1, 7, 28 and the last examination of the follow-up for each patient (range: 30-127 days). Best-corrected visual acuity (BCVA) and SD-OCT were performed for patient assessment, while various adverse events were recorded and analysed. At baseline, univariate analysis was also performed to examine the potential predictive factors for VMT release. RESULTS: 66.7 % of patients presented VMT release at the end of the follow-up, while 28.6 % exhibited MH closure. Baseline positive predictive factors for VMT release were young age, being female, phakic lens status, increased vitreofoveal angle, V-shaped and loose vitreomacular adhesion, small adhesion area, thin vitreous strands at the adhesion site and absence of an epiretinal membrane. Four new cases of ellipsoid line changes and subretinal fluid development became evident at day 7 compared to baseline. Lamellar macular hole (LMH) in four cases was first noticed at day 28 post injection. Formation of cystoid macular edema (CME) was noticed in three new cases at day 28 compared to baseline. CONCLUSIONS: Our study demonstrated a VMT release rate of 66.7 %. Apart from the known baseline factors that influence VMT release after ocriplasmin injection, the size of the vitreofoveal angle, a V-shaped and loose vitreomacular adhesion, a small adhesion area, and thin vitreous strands at the adhesion site, could additionally affect the outcome of VMT release. In addition, we studied when VMT release and concomitant events occur and for how long the induced complications lasted.
Authors: George P Theodossiadis; Irini P Chatziralli; Theodoros N Sergentanis; Ioannis Datseris; Panagiotis G Theodossiadis Journal: Graefes Arch Clin Exp Ophthalmol Date: 2014-10-15 Impact factor: 3.117
Authors: Marco Codenotti; Lorenzo Iuliano; Giovanni Fogliato; Giuseppe Querques; Francesco Bandello Journal: Graefes Arch Clin Exp Ophthalmol Date: 2014-04-25 Impact factor: 3.117
Authors: George P Theodossiadis; Vlassis G Grigoropoulos; Sofia Theodoropoulou; Ioannis Datseris; Panagiotis G Theodossiadis Journal: Am J Ophthalmol Date: 2014-01-18 Impact factor: 5.258
Authors: A P Lommatzsch; M Gutfleisch; M Dietzel; B Heimes; G Spital; M Böhme; N Bornfeld; D Pauleikhoff Journal: Klin Monbl Augenheilkd Date: 2014-04-30 Impact factor: 0.700
Authors: Marc D de Smet; Bart Jonckx; Marc Vanhove; Joachim van Calster; Peter Stalmans; Jean Marie Stassen Journal: Invest Ophthalmol Vis Sci Date: 2012-12-13 Impact factor: 4.799
Authors: Christoph Paul; P Krug; H H Müller; J Wachtlin; S Mennel; S Müller; S Schmitz-Valckenberg; T Bertelmann; R G Schumann Journal: Graefes Arch Clin Exp Ophthalmol Date: 2018-06-28 Impact factor: 3.117
Authors: Thomas Bertelmann; Joachim Wachtlin; Stefan Mennel; Michael J Koss; Mathias M Maier; Ricarda G Schumann; Sara Kazerounian; Hanna Daniel; Steffen Schmitz-Valckenberg Journal: Graefes Arch Clin Exp Ophthalmol Date: 2017-04-07 Impact factor: 3.117
Authors: Andrea Cacciamani; Roberto Gattegna; Marco Pileri; Marta Di Nicola; Sara Bardanzellu; Giuliana Facciolo; Pamela Cosimi; Andrea Govetto; Fabio Scarinci Journal: Int Ophthalmol Date: 2019-09-29 Impact factor: 2.031
Authors: Arshad M Khanani; Ryan N Constantine; Koenraad H Blot; Benedicte Lescrauwaet; Peter Szurman Journal: Acta Ophthalmol Date: 2020-12-26 Impact factor: 3.761
Authors: Edward William James Pritchard; Shams-Ulislam Ilyas; Soha Khaled Amar; Yit Chuin Yang; Nirodhini Narendran Journal: Clin Ophthalmol Date: 2016-01-12